Alpha 2.0
Login Register
» Articles » PMID: 6678879

Pharmacokinetics of High Dose Melphalan

Overview
Journal Invest New Drugs
Publisher Springer
Specialty Oncology
Date 1983 Jan 1
PMID 6678879
Citations 9
Authors
M R Hersh
T M Ludden
J G Kuhn
W A Knight 3rd
Affiliations
Soon will be listed here.
Abstract

A pharmacokinetic study of high dose intravenous melphalan, 180 mg/m2, was performed in eight patients. Plasma levels of melphalan declined in a biexponential fashion with a mean terminal half-life (t 1/2 beta) of 61 min (range 40.3-132.8 min). Estimated peak concentrations ranged from 5.45 to 16.57 mcg/ml. The average volume of distribution at steady state (Vdss) and clearance were 0.479 +/- 0.164 l/kg and 6.73 +/- 1.60 ml/min/kg, respectively. These kinetic parameters are similar to those reported from studies using lower doses of melphalan.

Citing Articles

Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies-Current Research and Clinical Approaches.

Poczta A, Rogalska A, Marczak A J Clin Med. 2021; 10(9).

PMID: 33922721 PMC: 8123041. DOI: 10.3390/jcm10091841.

Effect of Primary and Secondary Beads of Carbon Enterosorbent on Haematological Parameters and Oxidative Stress Development Caused by Melphalan in Rats.

Shevchuk O, Snezhkova E, Sarnatskaya V, Mikhailenko V, Glavin A, Makovetska L Medicina (Kaunas). 2019; 55(9).

PMID: 31480729 PMC: 6780921. DOI: 10.3390/medicina55090557.

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells.

Gourzones C, Bellanger C, Lamure S, Gadacha O, de Paco E, Vincent L Cancers (Basel). 2019; 11(4).

PMID: 30925767 PMC: 6521290. DOI: 10.3390/cancers11040439.

Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

Gomez E, Dulery R, Langlois C, Coiteux V, Terriou L, Magro L Bone Marrow Transplant. 2014; 49(12):1492-7.

PMID: 25222500 DOI: 10.1038/bmt.2014.193.

Fifty years of melphalan use in hematopoietic stem cell transplantation.

Bayraktar U, Bashir Q, Qazilbash M, Champlin R, Ciurea S Biol Blood Marrow Transplant. 2012; 19(3):344-56.

PMID: 22922522 PMC: 4337224. DOI: 10.1016/j.bbmt.2012.08.011.

References
1.
Brox L, Birkett L, Belch A . Pharmacology of intravenous melphalan in patients with multiple myeloma. Cancer Treat Rev. 1979; 6 Suppl:27-32. DOI: 10.1016/s0305-7372(79)80007-9. View
2.
Bosanquet A, Gilby E . Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol. 1982; 18(4):355-62. DOI: 10.1016/0277-5379(82)90006-2. View
3.
McElwain T, Hedley D, Burton G, Clink H, Gordon M, Jarman M . Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br J Cancer. 1979; 40(1):72-80. PMC: 2009972. DOI: 10.1038/bjc.1979.142. View
4.
Alberts D, Chang S, Chen H, MOON T, Evans T, Furner R . Kinetics of intravenous melphalan. Clin Pharmacol Ther. 1979; 26(1):73-80. DOI: 10.1002/cpt197926173. View
5.
Chang S, Alberts D, Melnick L, Walson P, Salmon S . High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci. 1978; 67(5):679-82. DOI: 10.1002/jps.2600670529. View